BioSig Technologies (BSGM) said late Monday that it has signed definitive agreements with an institutional investor for up to $1.1 billion in growth financing.
The deal includes a $100 million sale of senior secured convertible debentures and a $1 billion equity line of credit. The debentures carry a 4% annual interest rate rising to 18% in default, and mature in 24 months, the company said.
The equity line of credit allows BioSig to sell up to $1 billion of stock over 36 months, Biosig said.
Shares of BioSig were up 25% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。